New Therapy Engineers Cancer-Fighting Cells Inside Patients

Quick Smiles:

• Scientists have engineered cancer-fighting T-cells directly inside patients for the first time.
• This in vivo method may deliver treatments faster and at lower cost than traditional lab approaches.
• Early clinical trials have shown promising remission results in multiple myeloma patients.

In a significant medical breakthrough, researchers have replicated lab-based cancer therapy directly inside the bodies of myeloma patients. This innovation could make one of the leading non-chemotherapy treatments both faster and more affordable if widely adopted.

Traditionally, CAR T-cell therapy modifies a patient’s T-cells in a laboratory, adding a chimeric antigen receptor that helps the immune system target cancer cells. This process is often lengthy and costly, requiring specialized facilities outside the treatment hospital.

Now, two new clinical trials have demonstrated that this complex procedure can be performed within the patient, dramatically reducing wait times and potentially saving lives. The findings were recently shared at the American Society of Hematology’s annual meeting.

In the first trial, four individuals with multiple myeloma received the gene for the CAR directly in their bodies, enabling them to generate their own targeted T-cells. Two patients became free of detectable cancer cells, while the other two showed extended remission after several months.

“The question is no longer can you really do this,” said Yvonne Chen, a researcher at UCLA. “The question now is can you reach the level of efficacy that’s expected and will the safety profile meet the target.”

Although participants experienced some side effects, such as blood pressure drops and confusion, all made a full recovery. Notably, the flu-like symptoms seen in lab-based CAR T-cell methods were milder or absent.

A second trial replicated the approach in four more patients, leading to undetectable cancer levels in their bone marrow after one month. One maintained this cancer-free state five months later, and side effects in this group were less severe.

“I think it gives us a glimpse into the future,” shared hematologist Joy Ho. “In vivo CAR-T for multiple myeloma is here and hopefully it will stay.”

This streamlined method could open the door for many more patients to receive advanced CAR T-cell therapy. Researchers are also exploring this technology for non-cancer conditions, making it a hopeful step forward in medical science.

As advancements like these are embraced, more people could gain access to innovative treatments and brighter outcomes. Spread hope and share this amazing progress with your loved ones!

Source